Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Anticoagulation in Cardio-oncology
Author(s): Sebastian Szmit , Maciej Krzakowski , Dariusz M Kowalski , et al Added: 3 months ago

Anticoagulation

CV Disease in Special Populations
ESC 25: ESVM Guidelines on Interventional Treatment of VTE
Author(s): Oliver Schlager Added: 9 months ago
ESC Congress 2025 - New guidelines for catheter-based VTE therapy emphasise the importance of involving vascular experts, and performing procedures in experienced centers.Dr Oliver Schlager (Medical University of Vienna, AT) joins us to discuss the newly released 2025 ESVM Guidelines on Interventional Treatment of Venous Thromboembolism, endorsed by European national societies of Vascular… View more

Guidelines & Statements

Intervention
ESC 25: The HI-PRO Trial
Author(s): Gregory Piazza Added: 9 months ago
ESC Congress 2025 - HI-PRO shows apixaban 2.5mg twice daily reduced the risk of symptomatic recurrent venous thromboembolism when compared to placebo at 12 months.Dr Gregory Piazza (Brigham and Women's Hospital, US) joins us to discuss findings from the HI-PRO trial, evaluating extended-duration low-intensity apixaban versus placebo for secondary prevention in high-risk patients with provoked… View more

Anticoagulation

Vascular Disease and Surgery
Line Melgaard
Research Area(s) / Expertise:
Dr Line Melgaard MSc, PhD graduated from the University of Aalborg in 2013 with a master degree in Medicine with Industrial Specialization. Dr Melgaard received a PhD-degree from Aalborg University in 2016 (title: “Thromboembolic risk in heart failure patients without atrial fibrillation”). During her PhD, she used Danish nationwide registry data to investigate predictors of ischemic stroke and… View more
ACC 25 Late-Breaking Discussion: The API-Cat Study
Author(s): Harriette Van Spall , Isabelle Mahé Added: 1 year ago
ACC 25 - The API-CAT Study shows reduced-dose apixaban is non-inferior to full-dose apixaban for extended anticoagulation in patients with active cancer who have completed 6 months of anticoagulant therapy for venous thromboembolism (VTE).Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Prof Isabelle Mahe (Paris Cite University, Paris, FR) to discuss the… View more

Anticoagulation

Vascular Disease and Surgery
Research Area(s) / Expertise: Job title: Professor of Medicine in the Division of Pulmonary and Critical Care Medicine
30th Annual Meeting of the ISCP
Author(s): Maria Fernández García , Alberto Alen Andrés , Beatriz Nieves Ureña , et al Added: 2 months ago

Prevention & Chronic Conditions

CV Disease in Special Populations
Erik Klok
Research Area(s) / Expertise: Job title: Leiden University Medical Center, Leiden, NL
Erik Klok is Professor of Medicine and an internist specialising in vascular medicine at Leiden University Medical Center, Leiden, the Netherlands. His research focuses on venous thromboembolism, including diagnostic strategies, risk prediction, treatment and long-term complications. Erik Klok is also involved in studies aiming to improve care for patients with acute pulmonary embolism, including… View more
Could Acute COVID-19 Infection Ignite Thrombotic Risk?
Author(s): Joshua Stolker , Philippe Gabriel Steg , Roberta Rossini , et al Added: 1 year ago

COVID-19

MI/ACS
Research Area(s) / Expertise: Job title: Clinical Cardiologist and Professor of Vascular Biology